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Abstract Pheochromocytoma is a rare catecholamine secreting tumor that are usually arise 
from adrenal medulla and produces signs and symptoms of excessive catecholamine 
secretion from tumor. A 32 years old female presented to the hospital, with dyspeptic 
symptoms. She had fluctuative hypertension, palpitation and sweating. Abdominal 
ultrasonography showed a right adrenal mass, and computed tomography of the adrenal 
glands confirmed a right adrenal mass. However, clinical biochemistry tests specific for 
pheochromocytoma was not performed. Laparoscopic right adrenalectomy was done and 
the adrenal tumor was excised. Histopathology and immunohistochemistry confirmed the 
diagnosis of adrenal pheochromocytoma; the tumor cells being positive for chromogranin, 
synaptophysin, S-100 protein, and inhibin. Following the surgery, the patient did well and 
showed full recovery at follow-up after 1 month. 
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Abstrak. Feokromositoma merupakan tumor jarang yang mensekresi hormon katekolamin 
yang umumnya berasal dari medulla adrenal dan menghasilkan tanda dan gejala dari 
sekresi katekolamin yang berlebih dari tumor. Seorang wanita 32 tahun datang ke rumah 
sakit, dengan gejala dispepsia. Pasien memiliki hipertensi yang fluktuatif, palpitasi dan 
berkeringat banyak, Ultrasonografi abdominal menunjukkan adanya massa adrenal kanan. 
Namun, pemeriksaan biokimia spesifik untuk feokromositoma tidak diperiksakan. Pada 
pasien dilakukan laparoskopi adrenalektomi kanan dan dilakukan eksisi tumor adrenal. 
Hasil histopatologi dan imunohistokimia menunjukkan suatu feokromositoma adrenall 
terdapat sel tumor yang positif untuk chromogranin,syntaptophysin, S-100 protein, dan 
inhibin. Setelah dilakukan pembedahan, pasien tidak memiliki keluhan dan tampak kembali 
sehat setelah 1 bulan pembedahan. 
Kata Kunci: Feokromositoma Adrenal, Hipertensi, Metanefrin 
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1. Introduction 
Catecholamine-secreting tumor, pheochromocytoma, is a rare neoplasm that derived from 
chromaffin tissue on the adrenal medulla. Prevalence of pheochromocytomas is estimated 
between 0,05% and 0,1% of patients with hypertension or 3 to 8 people per million per year in 
general population. Peak incidence occurs during the fourth and fifth decades of life [1],[2]. 
However, as illustrated by autopsy studies, the average delay in diagnosis is almost 3 years and 
in 0,05% to 0,1% of the patients, or even missed during life [3]. Here, we present a rare case of 
secondary hypertension due to giant adrenal pheochromocytoma. 
2. Case Ilustration   
A 32-year-old woman, visited hospital with complaints of dyspepsia for the past 3 months. She 
was investigated elsewhere for dyspeptic symptoms and was found to have a right adrenal mass 
of 7,5 cm in diameter on screening ultrasound. On systemic examination, she was found 
hypertension and tachycardia. Patient has known hypertension for 1 year. However, the blood 
pressure has a tendency to fluctuate. She was prescribed calcium channel blockers (amlodipine 
10 mg once daily). In addition, she also had palpitations, headache and sweating for the past 4 
months. Each attack persists for few minutes to half an hour and occurs irregularly. Physical 
examination revealed no edema nor obesity. Abdomen was soft, no tenderness, no palpable 
masses, no organomegaly, and no ascites. Her bowel sounds normal.  
ECG showed normal tachycardia. An ultrasonography of abdomen showed a right adrenal mass. 
She then had Computed Tomography (CT) scan of abdomen and revealed right sided adrenal 
mass of a size of 9,05 cm x 7,68 cm x 9 cm (Figure 1). We made a provisional diagnosis of 
secondary hypertension due to adrenal pheochromocytoma. However, for confirming diagnosis, 
we need to do biochemical investigations i.e. 24-hour urinary metanephrine level or fractionated 
metanephrines in plasma, which patient refused to. Cortisol level was normal (17,36 ug/dL). 
With written consent, patient was prepared for right open adrenalectomy with all precautions 
were taken and prepared for managing the preoperative hypertensive crisis. Right 
adrenalectomy was then performed. The patient was extubated and was kept in the intensive 
care unit for 48 hours. There were no untoward events in the postoperative period, patient 
remained normotensive in the postoperative period and the patient was discharge home on the 
10th day. 
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Figure 1 MSCT/CT scan abdomen with contrast 
 
Gross examination of the right adrenal gland showed a nodular mass with the measurements of 
9.5 x 8 x 6 cm, brown, encapsulated, and surrounding with fat. The microscopy sections showed 
a zellballen nests of chromaffin cells with vascular invasion, round/oval nuclei, pleomorphic, 
and areas of brown fat, suggested pheochromocytoma in the adrenal gland. 
Immunohistochemisty of the tumor cells were positive for chromogranin, synaptophysin, 
inhibin and S-100 protein. They were negative for calretinin, melanA, bcl2 (Figure 2.). 
 
Figure 2 Immunohistochemistry of tumor cells: A) Chromogranin; B) synapthophysin; 
C) S-100 
 
The patient was followed up in the hospital after 1 month, the blood pressure was normal. Six 
weeks after surgery, 24-hour urinary metanephrine revealed normal level of metanephrine (58 
mcg/24 h), normal level of normetanephrine (353 mcg/24 h), and normal total metanpehrine 
(411 mcg/24 h). She has then been advised to follow up periodically in order to rule out 
recurrence. 
3. Discussion 
Over the last 2 decades, incidence of adrenal incidentalomas has dramatically increased as a 
result of a widespread use of abdominal imaging modalities, including ultrasound, CT, and 
magnetic resonance imaging (MRI). An understanding of the differential diagnosis of adrenal 
masses, a biochemical profile of hyperfunctioning adrenal tumors, and assessment of the risk 
factors for malignancy of adrenal is required in the evaluation of adrenal incidentalomas. 
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Patients with hyperfunctioning tumors and those with potentially malignant lesions need to 
performed adrenalectomy, afterwards. Factors that influencing the decision include the size and 
the nature of lesion [4]. 
Functioning adrenal tumors, even pheochromocytoma, are not always found, even when signs 
of adrenal hormone excess are evident. Approximately 30% of pheochromocytomas are found 
as incidentalomas, and later diagnosed accurately as pheochromocytomas. During screening for 
adrenal tumors, elevated plasma and urine catecholamines is essential for diagnosing 
pheochromocytoma. Urinary catecholamines and their metabolites can be measured accurately 
in 24-hour urine, while plasma catecholamines levels are often affected by various conditions, 
such as hypertonic status and stress [4].  
Signs and symptoms of pheochromocytoma, as a result from hemodynamic and metabolic 
action of circulating catecholamine, typically present with hypertension, unusual sweating, 
headache, frequent arrhythmias, and pallor during hypertension episode [1],[2]. However, giant 
pheochromocytoma, >7 cm in size, may not present with these symptoms. This is probably due 
to the presence of tumor necrosis, high loads of interstitial tissue compared to chromaffin cells 
or lack of catecholamine secretion due to encapsulation by connective tissue [5].  
Diagnosis of pheochromocytoma is confirmed by elevation of metanephrine and catecholamine 
production, supported with radiologic studies [1]. However, prior to ordering biochemical 
testing, detailed medical history including a family history and factors that may provoke 
paroxysms is an essential requirement. On localizing tumor, CT scanning is the preferred 
imaging modality to MRI because its outstanding spatial resolution is superior. It has 90% of 
sensitivity and 75% to 80% of specificity for adrenal tumor [3].  
To prevent cardiovascular complications, it is always indicated to perform surgical removal of 
the tumor [6]. 
The most important goal for preoperative management of a pheochromocytoma patient is to 
normalize heart rate, blood pressure, function of other organs, and prevent a patient from a 
surgery-induced catecholamine-storm by giving the combination of alpha and beta blockade [2], 
[7]. Surgical resection of the tumor is the treatment of choice for pheochromocytoma, with 
result of cured hypertension [7]. However, 25% of patients remain hypertension, possibly due to 
coexisting hypertension. Laparoscopic removal of pheochromocytoma should be limited to a 
diameter of 4 cm, while open surgical exploration is indicated when tumors are large, multiple, 
or difficult to remove by laparoscopy [8]. In postoperative period, monitoring blood pressure, 
heart rate, and blood glucose is recommended in conjunction with the adjustment of associated 
therapy [9]. To determine whether the tumor has completely removed or not, measurement of 
urine or plasma metanephrines is recommended at 2 to 6 weeks after surgery [3].  
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Since there were no histological criteria nor scoring systems has been described to differentiate 
between malignant and benign pheochromocytoma, in 2017, World Health Organization 
(WHO) made the classification of endocrine tumor (benign pheochromocytoma and malignant 
pheochromocytoma) into a single section; pheochromocytoma [10].  
Generally, 90% of patients is cured after surgical removal, yet a persistent risk of local or 
metastatic recurrences or a new tumor appears in 5% during 5 years follow-up [3]. To assess 
recurrent or metastatic disease, lifelong annually biochemical testing is suggested [9]. If 
biochemical test is elevating persistently, additional imaging studies are indicated [3]. 
4. Conclusion 
We have reported a rare case of giant adrenal pheochromocytoma. Adrenal pheochromocytoma 
was confirmed by clinical, imaging, and histopathology findings. Even though 
pheochromocytoma causes hypertension in 0,1%, early detection is crucial, not only for the 
potential treatment of hypertension but also to prevent the potential fatal condition of the 
unrecognized tumor.  
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